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Introduction
By the year 2020, it is predicted that more than 16% of
people in the United States will be 65 years of age or
older1. In Taiwan, people in that age range were more
than 7% of the population in 1993 and are expected to
occupy 10% of the population by 2011 and 20% by 2030.
Not unusually, older individuals have a number of
diseases such as cardiovascular disorders and arthritis
that are treated with antiplatelet agents or nonsteroidal
anti-inflammatory drugs (NSAIDs)1. Although the over-
all incidence of spontaneous bleeding and perforation
of peptic ulcers has decreased, those complications
are on the rise among people who use NSAIDs2. These
agents are associated not only with an increased risk
of peptic ulcer disease and its complications but also
with higher expenses for the prescription of gastropro-
tective drugs and for hospitalization for gastrointesti-
nal (GI) hemorrhage3–6. Several risk factors may identify
patients prone to adverse effects of NSAID therapy, with
advanced age consistently found to be one of them7.
Health care professionals must thus be conversant
with the problem of NSAID-related GI bleeding in the
elderly, as they will likely see more and more older
patients with this complication. We reviewed the English-
language literature on this topic using the search terms
“elderly”, “GI bleeding”, and “NSAID”.
Age-related Physiologic Changes 
in the GI Tract
With aging, various changes occur in the GI tract. The
esophageal sphincter pressure decreases, and hiatal
hernia is not uncommon in the elderly who are there-
fore frequently subject to gastroesophageal reflux. 
In the stomach, atrophy of mucosa and achlorhydria
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are not unusual and may induce gastritis, hypergas-
trinemia, decreased gastric emptying, and bacterial
overgrowth1. In the US population above 60 years of
age, the prevalence of Helicobacter pylori is approxi-
mately 50%, compared with approximately 10% in those
less than 20 years of age. This increasing prevalence 
of H. pylori infection in the elderly may also increase
the risk of type B chronic gastritis, gastric atrophy,
peptic ulcer disease, and neoplasm8. H. pylori infec-
tion and NSAIDs are independent and synergistic risk
factors for both uncomplicated and bleeding peptic
ulcer9. Finally, diverticulae are more common in the
elderly, are a possible source of obscure GI bleeding,
and thus may further confuse the situation.
Pathogenesis of NSAID-related Peptic 
Ulcer Disease
NSAIDs induce GI mucosal injury, which may then result
in ulcers and bleeding. Pathogenesis of NSAID-induced
mucosal injury can generally be divided into topical
and systemic effects.
Topical injury
By creating a near-neutral pH at the epithelial surfaces
in the stomach and the duodenum, secretion of bicar-
bonate from the duodenum into the mucus gel layer
provides the first line of protection against luminal
acid10. The acidic properties of aspirin or NSAIDs are
responsible for initiation of mucosal injury. NSAIDs
can cause topical damage by decreasing the hydropho-
bic properties of gastric mucus, allowing endogenous
gastric acid and pepsin to injure the surface epithelium.
Indirect mechanisms may also contribute to topical
injury, such as duodenogastric reflux of active NSAID
metabolites or bile7.
Systemic effects
The systemic effects of NSAIDs are mediated by
decreased synthesis of mucosal prostaglandins7,11.
Prostaglandins are derived from arachidonic acid, a
substance derived from cell-membrane phospholipids
through the action of phospholipase A. The metabo-
lism of arachidonic acid to prostaglandins is catalyzed
by cyclooxygenase (COX), an enzyme with two distinct
forms, COX-1 and COX-2. Although structurally similar,
these two isoenzymes have different properties. COX-1
is produced in virtually all body tissues, including the GI
tract, platelets, endothelial cells, renal medullary col-
lecting ducts, and interstitium. It is essential for main-
taining GI integrity, platelet aggregation, and sodium
and water balance. Mucosal prostaglandins defend the
gastric and duodenal mucosa against injury and ulcer-
ation by stimulating several factors that contribute to
normal mucosal integrity12. These factors include mucus
synthesis and secretion, mucosal bicarbonate secretion,
mucosal blood flow, and cellular repair13. COX-2, nor-
mally present in the brain and kidney cells, is expressed
in high concentrations at sites of inflammation and
carcinogenesis. Traditional NSAIDs are nonselective
inhibitors of both COX-1 and COX-2 isoenzymes. The
anti-inflammatory properties of NSAIDs are mediated
through inhibition of COX-2, whereas adverse effects,
such as gastroduodenal ulceration, occur as a result of
suppression of constitutively expressed COX-17,14. By
inhibiting prostaglandin synthesis, NSAIDs compromise
the gastroduodenal defense mechanism including blood
flow and secretion of mucus and bicarbonate. Because
these agents are used so frequently and so commonly
cause mucosal damage, NSAIDs are the most widely
reported drugs causing adverse events15.
Attempts have been made to reduce the topical
damage induced by NSAIDs by using enteric-coated
preparations or parenteral or rectal administration.
However, the systemic effects cannot be avoided, so
ulcers may still develop. Doses of aspirin as low as 30mg
are sufficient to suppress prostaglandin synthesis in the
gastric mucosa7.
NSAID-related GI Bleeding in the Elderly
Choudari et al. compared the outcome in patients with
bleeding from NSAID-related and non-NSAID-related
peptic ulcers16. Seventy-six patients with NSAID-related
disease were older and more likely to have cardiores-
piratory disease than the 112 patients with non-NSAID-
related ulcers. The outcome of the bleeding itself did
not differ significantly between the 2 groups. However,
those with NSAID-related disease were hospitalized for
significantly longer, most likely because of their other
conditions16. While NSAIDs may be prescribed for a vari-
ety of reasons in the elderly, 1 prominent indication is
to provide antiplatelet activity to reduce cardiovascu-
lar mortality. It is ironic that a medication given to
reduce cardiovascular risk may lead to bleeding—a
potential contributing factor to increased cardiovascular
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morbidity and mortality. A series of 991 patients with
coronary artery disease on low-dose aspirin followed in
Hong Kong for 2 years found a relatively low incidence
of GI bleeding—1.5% per year. They had no deaths
related to the bleeding in this series, but the morbidity
associated with bleeding was significant17. The risks and
benefits of prophylactic low-dose aspirin in the elderly
must therefore be weighed very carefully.
Overall, the reported incidence of clinically apparent
upper GI events is 3–4.5% of patients taking NSAIDs,
with serious complications developing in approximately
1.5% of patients18. The mortality among patients who
are hospitalized for NSAID-induced upper GI bleeding
is about 5–10%19. Compared with nonusers of NSAIDs,
elderly people taking these agents have a 5.5-fold
increased risk of gastric ulcer and a 4.3-fold higher risk
of duodenal ulcer4. In people below 65 years of age,
NSAIDs increase the risk of GI bleeding 1.65-fold, but
in those 65 years and above, the risk is approximately
5.5-fold higher than in people not taking NSAIDs, a
risk that increases linearly with age7,20,21. Therefore, 
a history of peptic ulcer in an elderly patient should
generally be regarded as a relative contraindication to
NSAIDs22. It should also be noted that NSAIDs or aspirin
may also increase the risk of diverticular bleeding in
the elderly21.
Diagnosis of NSAID-related GI Bleeding
The clinical diagnosis of ulcer disease is often difficult.
Pain may be masked for a number of reasons, perhaps
even by the analgesic property of NSAIDs themselves.
On the other hand, indigestion and upper abdominal
pain are quite common but may have a variety of causes,
of which ulcer is only 1 possibility.
Fecal occult blood testing can be used to look for
GI bleeding, but its utility is limited because of insuffi-
cient sensitivity and specificity. Certainly, any patient
using NSAIDs who has a positive stool test ought to
undergo esophagogastroduodenoscopy (EGD) or, if that
cannot be tolerated, a barium study23. EGD is clearly
the most reliable tool for the diagnosis of ulceration of
the upper GI tract. However, ulcerations may be present
beyond the duodenum. In the event that neither EGD
nor colonoscopy demonstrates an obvious lesion, the
source of occult bleeding may be further sought by using
push-enteroscopy, capsule endoscopy, or double-balloon
enteroscopy, all of which are means of evaluating the
small bowel24. Other than capsule endoscopy, how-
ever, these studies may be uncomfortable and not well
tolerated by the elderly. A sucrose permeability test has
been suggested as a test for NSAID-induced GI damage,
but it is only of limited usefulness since it cannot define
the location or severity of a lesion25,26.
Treatment and Prevention
Other than avoiding unnecessary use of NSAIDs, there
are several strategies to manage elderly patients who
must take the drugs but who are prone to or have
already experienced GI bleeding.
Switch to COX-2 selective inhibitor
The COX-2-selective NSAIDs were specifically designed
to provide pain relief comparable to that of traditional
NSAIDs while reducing the incidence of adverse GI events
in the elderly27. These agents are less likely to suppress
mucosal prostaglandin secretion than the traditional
nonselective NSAIDs. The incidence of acid-related GI
disorders in the elderly is reportedly less than half as
great with COX-2-selective than with traditional NSAIDs
(6% vs. 13%)28. However, rofecoxib and valdecoxib
were recently withdrawn from the market because of
serious cardiovascular adverse events. Surveillance of
the safety of the other COX-2 inhibitors is currently
ongoing29.
Misoprostol
A different approach to mucosal protection but still
focusing on preserving the protective effect of prosta-
glandins is the administration of misoprostol, a prosta-
glandin analog, along with NSAIDs. Although effective,
its utility is frequently limited by side effects30. In addi-
tion, in patients with a history of peptic ulcer, miso-
prostol has no significant protective effect against the
risk of rebleeding31. Although prostaglandins are useful
in preventing NSAID-induced gastroduodenal mucosal
injury, their role in the treatment of already established
NSAID-associated ulcers is unclear7.
Mucosal protective agents
Sucralfate, a basic aluminum salt of sucrose octasulfate,
is effective in the treatment of both NSAID- and non-
NSAID-related duodenal ulcers. It appears to be as
effective as H2-receptor antagonists in the healing of
non-NSAID-related gastric ulcers7. Long-term sucralfate
therapy may reduce GI symptoms and therefore improve
compliance with NSAID treatment of any type32. In 
1 study, sucralfate reportedly reduced the incidence of
NSAID-related ulcers from 28% to 8%33.
Histamine H2-receptor antagonists
Treatment of peptic ulcer disease with conventional
doses of H2-receptor antagonists for 6–12 weeks results
in the healing of approximately 75% of gastric and
87% of duodenal ulcers, despite the continued use 
of NSAIDs. However, continuation of NSAIDs appears
to result in delayed healing, and the final outcome 
is largely dependent on the initial size of the ulcer7.
H2-receptor antagonists are relatively safe drugs that are
widely available over the counter without a doctor’s
prescription. However, drug metabolism in the elderly
differs from that of younger people. In general, renal
function decreases with age, and it may be even worse
in elderly with comorbid illnesses. Dosages of the renally
cleared H2-receptor antagonists should, therefore, be
adjusted accordingly. In addition, cimetidine is known
to inhibit cytochrome p450, thereby increasing the
serum concentration of drugs normally metabolized by
that enzyme, such as calcium channel blockers, ben-
zodiazepines, and lovastatin. Cimetidine should be
replaced with other H2-receptor antagonists, which do
not have the same effect on hepatic drug metabolism,
particularly in elderly individuals who are quite likely
to be on such drugs34.
Proton pump inhibitors (PPIs)
PPIs have a demonstrated role in the treatment and pre-
vention of both aspirin and nonselective NSAID-related
upper GI damage29,35. Even patients on COX-2-selective
NSAIDs may benefit from PPI cotherapy36. In the treat-
ment of NSAID-related peptic ulcer disease, PPIs are
much more effective than H2-receptor blockers. In 
1 study, PPI was associated with a significantly better
risk reduction for peptic ulcers in both acute and
chronic NSAID users than were H2-receptor blockers
37.
Eradication of H. pylori
In addition to its importance in treating ulcers, eradi-
cation of H. pylori is considered necessary to prevent GI
bleeding in patients on low-dose aspirin or NSAIDs38–40.
However, routine testing for and eradication of H. pylori
infection have not been recommended for patients at
no or low risk of peptic ulcer disease41. Current evidence
suggests that H. pylori eradication reduces the ulcer
risk for patients who are being started on NSAIDs but
not for those already on long-term NSAID therapy42.
Conclusion
Aging is inevitable, and the elderly are often subject to
chronic diseases. In these patients, NSAIDs are a 2-
edged sword. They may well be useful for treatment or
secondary prevention of the diseases to which these
patients are susceptible. However, they also clearly pose
a risk of bleeding, to which the elderly are more
prone. Proper patient selection is important. A history
of peptic ulcer should be regarded as a relative con-
traindication to the use of NSAIDs. When they must be
given, however, the use of gastroprotective agents will
probably reduce the incidence of bleeding associated
with them22. Weighing of the benefit-risk ratio, how-
ever, goes beyond the decision for any 1 patient. In
Taiwan, H2-receptor blockers and PPIs are relatively
expensive drugs, and the National Health Insurance
Bureau does not cover their routine prescription for
elderly patients taking NSAIDs. This policy should be
carefully examined in light of the following question. 
In the long run, which will cost more: covering the cost
of drugs that may help protect against NSAID-induced
GI bleeding or caring for elderly patients who develop
this complication?
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